These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38937736)

  • 1. Alteration of the immune microenvironment in the axillary metastatic lymph nodes of luminal A breast cancer patients.
    Wu M; Wang S; Yuan K; Xiong B; Li Y; Lyu S
    World J Surg Oncol; 2024 Jun; 22(1):172. PubMed ID: 38937736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors.
    Glajcar A; Łazarczyk A; Tyrak KE; Hodorowicz-Zaniewska D; Streb J; Okoń K; Szpor J
    Virchows Arch; 2021 Nov; 479(5):871-882. PubMed ID: 34117905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
    Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
    BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
    Tawfik O; Kimler BF; Karnik T; Shehata P
    Hum Pathol; 2018 Oct; 80():170-178. PubMed ID: 29936058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.
    Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
    BMC Cancer; 2018 Feb; 18(1):123. PubMed ID: 29390966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Tomioka N; Hatanaka KC; Okuyama D; Watanabe KI; Yamamoto M; Maeda H; Tachikawa H; Kuwahara S; Shimizu A; Suzuki H; Hatanaka Y; Takahashi M
    Breast Cancer; 2023 May; 30(3):497-505. PubMed ID: 36892732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune parameters associated with survival in metaplastic breast cancer.
    Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
    Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional CD3
    Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement.
    Macchetti AH; Marana HR; Silva JS; de Andrade JM; Ribeiro-Silva A; Bighetti S
    Clinics (Sao Paulo); 2006 Jun; 61(3):203-8. PubMed ID: 16832552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer.
    Kohrt HE; Nouri N; Nowels K; Johnson D; Holmes S; Lee PP
    PLoS Med; 2005 Sep; 2(9):e284. PubMed ID: 16124834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
    Kakavand H; Vilain RE; Wilmott JS; Burke H; Yearley JH; Thompson JF; Hersey P; Long GV; Scolyer RA
    Mod Pathol; 2015 Dec; 28(12):1535-44. PubMed ID: 26403784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of TIM-3 expression by CD4
    Shariati S; Ghods A; Zohouri M; Rasolmali R; Talei AR; Mehdipour F; Ghaderi A
    Mol Immunol; 2020 Dec; 128():47-54. PubMed ID: 33068833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis.
    Shao GL; Wang MC; Fan XL; Zhong L; Ji SF; Sang G; Wang S
    Technol Cancer Res Treat; 2018 Jan; 17():1533034617754024. PubMed ID: 29529946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
    Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
    Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.